Barrett's esophagus, markers to distinguish risk groups

Area of Science:

• Gastroenterology and Oncology
• Molecular Pathology
• Cancer Biomarkers

Background:

• Barrett's esophagus (BE) confers a 30-40 fold increased risk of esophageal adenocarcinoma compared to the general population.
• Early detection of preneoplastic changes in BE is crucial for effective surgical intervention and improved patient prognosis.
• Epithelial dysplasia grading, while standard, suffers from inter- and intra-observer variability, necessitating alternative risk markers.

Purpose of the Study:

• To identify parameters beyond dysplasia that can differentiate risk levels in BE patients.
• To enable a differentiated follow-up strategy for cost-effective and timely diagnosis.
• To facilitate early surgical intervention for potentially curative treatment.

Main Methods:

• Histochemical analysis of p53, c-erb-2, PCNA, and CEA in 27 patients (9 BE without dysplasia, 9 BE with dysplasia, 9 adenocarcinomas).
• Static cytometry to assess aneuploidy.
• Correlation of biomarker expression and aneuploidy with disease progression.

Main Results:

• PCNA was detected in all groups, but less frequently on the surface epithelium in controls.
• C-erb-2 and p53 showed increasing positivity with progression from BE to dysplasia to adenocarcinoma.
• CEA was positive in most controls and all dysplasia/adenocarcinoma cases.
• Aneuploidy was detected in controls, dysplasia, and all adenocarcinomas, suggesting genomic instability.

Conclusions:

• Positive biomarker expression, even without dysplasia, indicates genomic instability and potential malignancy progression.
• The study establishes three distinct risk groups (high, low, intermediate) for BE patients.
• A differentiated follow-up based on these markers allows for early diagnosis and cost-effective management.